Nutex Health (NUTX) 10-Q 22 Aug 22 2022 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2022	Aug. 22, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2022
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	000-53862
Entity Registrant Name	NUTEX HEALTH INC.
Entity Central Index Key	0001479681
Entity Tax Identification Number	11-3363609
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	6030 S. Rice Ave
Entity Address, Address Line Two	Suite C
Entity Address, City or Town	Houston
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	77081
City Area Code	713
Local Phone Number	660-0557
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	NUTX
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		649,770,069

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 47,600,621	$ 36,118,284
Accounts receivable	94,653,853	112,766,317
Accounts receivable - related parties	1,391,049	1,993,117
Inventories	2,907,182	2,814,178
Prepaid expenses and other current assets	2,427,849	323,283
Total current assets	148,980,554	154,015,179
Property and equipment, net	67,822,682	151,912,500
Operating right-of-use assets	23,686,253	21,829,552
Financing right-of-use assets	183,542,400	64,614,781
Intangible assets, net	21,964,230	682,649
Goodwill	425,355,837	1,139,297
Other assets	441,304	456,085
Total assets	871,793,260	394,650,043
Current liabilities:
Accounts payable	19,954,714	13,582,664
Accounts payable - related parties	3,614,326	4,070,438
Lines of credit	2,592,714	72,055
Current portion of long-term debt	7,735,760	10,158,932
Operating lease liabilities, current portion	1,789,871	1,489,997
Financing lease liabilities, current portion	3,592,382	1,452,447
Accrued expenses and other current liabilities	17,191,260	6,864,426
Total current liabilities	56,471,027	37,690,959
Long-term debt, net	16,305,258	78,821,985
Operating lease liabilities, net	22,616,233	20,820,588
Financing lease liabilities, net	192,516,749	65,735,501
Deferred tax liabilities	17,469,750	0
Total liabilities	305,379,017	203,069,033
Equity:
Common stock, $0.001 par value; 900,000,000 shares authorized; 648,918,458 and 592,791,712 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively	648,918	592,792
Additional paid-in capital	467,402,221	11,742,891
Retained earnings	57,638,688	102,315,623
Nutex Health Inc. equity	525,689,827	114,651,306
Noncontrolling interests	40,724,416	76,929,704
Total equity	566,414,243	191,581,010
Total liabilities and equity	$ 871,793,260	$ 394,650,043

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	900,000,000	900,000,000
Common stock, shares issued	648,918,458	592,791,712
Common stock, shares outstanding	648,918,458	592,791,712

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenue:
Total revenue	$ 58,047,933	$ 62,814,672	$ 137,175,175	$ 150,157,914
Operating costs and expenses:
Payroll	24,045,279	18,261,313	48,502,680	36,026,695
Contract services	13,478,349	4,235,963	18,883,944	9,036,276
Medical supplies	2,581,552	2,572,970	6,841,031	4,972,662
Insurance expense	1,551,696	1,971,574	3,927,679	3,619,305
Depreciation and amortization	3,132,485	2,223,461	5,529,346	4,001,640
Other	8,266,046	4,412,059	14,099,991	8,714,161
Total operating costs and expenses	53,055,407	33,677,340	97,784,671	66,370,739
Gross profit	4,992,526	29,137,332	39,390,504	83,787,175
Corporate cost:
Acquisition costs	3,885,666	0	3,885,666	0
General and administrative expenses	2,485,337	1,533,002	7,644,342	3,522,040
Total corporate cost	6,371,003	1,533,002	11,530,008	3,522,040
Operating income (loss)	(1,378,477)	27,604,330	27,860,496	80,265,135
Interest expense	3,849,629	1,504,933	5,705,603	2,991,090
Other expense (income)	(1,403,222)	(4,060,149)	977,323	(3,921,356)
Income (loss) before taxes	(3,824,884)	30,159,546	21,177,570	81,195,401
Income tax expense	19,653,286	481,501	19,829,609	638,354
Net income (loss)	(23,478,170)	29,678,045	1,347,961	80,557,047
Less: net income (loss) attributable to noncontrolling interests	(4,082,418)	2,618,644	(786,589)	15,735,510
Net income (loss) attributable to Nutex Health Inc.	$ (19,395,752)	$ 27,059,401	$ 2,134,550	$ 64,821,537
Earnings (loss) per common share
Basic	$ (0.03)	$ 0.05	$ 0	$ 0.11
Diluted	$ (0.03)	$ 0.05	$ 0	$ 0.11
Weighted average shares outstanding
Basic	646,370,173	592,791,712	619,728,949	592,791,712
Diluted	658,991,192	592,791,712	626,992,817	592,791,712
Hospital Division [Member]
Revenue:
Total revenue	$ 51,604,679	$ 62,814,672	$ 130,731,921	$ 150,157,914
Population Health Management Division [Member]
Revenue:
Total revenue	$ 6,443,254	$ 0	$ 6,443,254	$ 0

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Total
Beginning balance, value at Dec. 31, 2020	$ 592,792	$ 9,724,052	$ 81,413,212	$ 55,638,769	$ 147,368,825
Beginning balance, shares at Dec. 31, 2020	592,791,712
Contributions		791,610		4,176,800	4,968,410
Distributions			(30,054,155)	(8,831,693)	(38,885,848)
Net loss			37,762,136	13,116,866	50,879,002
Ending balance, value at Mar. 31, 2021	$ 592,792	10,515,662	89,121,193	64,100,742	164,330,389
End balance, shares at Mar. 31, 2021	592,791,712
Contributions		1,243,686		4,821,304	6,064,990
Distributions			(30,785,270)	(8,775,526)	(39,560,796)
Net loss			27,059,401	2,618,644	29,678,045
Ending balance, value at Jun. 30, 2021	$ 592,792	11,759,348	85,395,324	62,765,164	160,512,628
End balance, shares at Jun. 30, 2021	592,791,712
Beginning balance, value at Dec. 31, 2021	$ 592,792	11,742,891	102,315,623	76,929,704	191,581,010
Beginning balance, shares at Dec. 31, 2021	592,791,712
Contributions				3,869,201	3,869,201
Distributions			(27,114,936)	(5,738,045)	(32,852,981)
Net loss			21,442,843	3,383,288	24,826,131
Ending balance, value at Mar. 31, 2022	$ 592,792	11,742,891	96,643,530	78,444,148	187,423,361
End balance, shares at Mar. 31, 2022	592,791,712
Beginning balance, value at Dec. 31, 2021	$ 592,792	11,742,891	102,315,623	76,929,704	191,581,010
Beginning balance, shares at Dec. 31, 2021	592,791,712
Deconsolidation of Real Estate Entities					39,323,872
Ending balance, value at Jun. 30, 2022	$ 648,918	467,402,221	57,638,688	40,724,416	566,414,243
End balance, shares at Jun. 30, 2022	648,918,458
Beginning balance, value at Mar. 31, 2022	$ 592,792	11,742,891	96,643,530	78,444,148	187,423,361
Beginning balance, shares at Mar. 31, 2022	592,791,712
Reverse acquisition with Clinigence	$ 50,961	446,780,842		194,747	447,026,550
Reverse acquisition with Clinigence , shares	50,961,109
Notes payable converted to common stock	$ 2,623	4,062,749			4,065,372
Notes payable converted to common stock, shares	2,622,819
Common stock issued for exercise of warrants	$ 2,147	4,116,994			4,119,141
Common stock issued for exercise of warrants , shares	2,147,252
Common stock issued for exercise of options	$ 312	644,662			$ 644,974
Common stock issued for exercise of options , shares	312,019				312,019
Restricted stock awards issued for compensation	$ 83	54,083			$ 54,166
Restricted stock awards issued for compensation , shares	83,547
Deconsolidation of Real Estate Entities			(12,267,888)	(27,055,984)	(39,323,872)
Contributions				861,916	861,916
Distributions			(7,341,202)	(7,637,993)	(14,979,195)
Net loss			(19,395,752)	(4,082,418)	(23,478,170)
Ending balance, value at Jun. 30, 2022	$ 648,918	$ 467,402,221	$ 57,638,688	$ 40,724,416	$ 566,414,243
End balance, shares at Jun. 30, 2022	648,918,458

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash flows from operating activities:
Net income	$ 1,347,961	$ 80,557,047
Adjustment to reconcile net income to net cash from operating activities:
Depreciation and amortization	5,529,346	4,001,640
Stock-based compensation expense	54,166	0
Other income - gain on PPP loan forgiveness	0	(4,525,600)
Deferred tax expense	12,013,748	0
Debt accretion expense	722,536	0
Non-cash lease expense	109,114	(144,677)
Changes in operating assets and liabilities:
Accounts receivable	19,745,666	17,338,754
Accounts receivable - related party	602,068	(150)
Inventories	(93,004)	(2,513)
Prepaid expenses and other current assets	(1,977,182)	(1,022,062)
Accounts payable	6,358,427	4,845,359
Accounts payable - related party	(630,490)	(793,487)
Accrued expenses and other current liabilities	9,645,922	2,536,291
Other current assets	(25,219)	(36,120)
Net cash from operating activities	53,403,059	102,754,482
Cash flows from investing activities:
Acquisitions of property and equipment	(16,621,726)	(21,714,755)
Acquired cash in reverse acquisition with Clinigence	12,716,228	0
Cash related to deconsolidation of Real Estates Entities	(2,421,212)	0
Net cash from investing activities	(6,326,710)	(21,714,755)
Cash flows from financing activities:
Proceeds from lines of credit	2,592,714	0
Proceeds from notes payable	4,865,974	13,966,345
Repayments of lines of credit	(72,055)	(813,101)
Repayments of notes payable	(4,338,567)	(13,712,534)
Repayments of finance leases	(305,134)	(549,710)
Common stock issued for exercise of warrants	4,119,141	0
Common stock issued for exercise of options	644,974	0
Members' contributions	4,731,117	11,033,400
Members' distributions	(47,832,176)	(78,446,644)
Net cash from financing activities	(35,594,012)	(68,522,244)
Net change in cash and cash equivalents	11,482,337	12,517,483
Cash and cash equivalents - beginning of the period	36,118,284	25,514,275
Cash and cash equivalents - end of the period	47,600,621	38,031,758
Supplemental disclosures of cash flow information:
Cash paid for interest	5,705,603	2,991,090
Cash paid for income taxes	631,400	316,702
Non-cash investing and financing activities:
Acquisition of financing leases	$ 9,937,104	$ 452,457

Organization and Operations

Organization and Operations	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Organization and Operations	Note 1 – Organization and Operations Nutex Health Inc. (“Nutex Health” or the “Company”), is a physician-led, technology-enabled healthcare services company with 21 hospital facilities in eight states (hospital division), and a primary care-centric, risk-bearing population health management division. Our hospital division implements and operates different innovative health care models, including micro-hospitals, specialty hospitals and hospital outpatient departments (“HOPDs”). The population health management division owns and operates provider networks such as independent physician associations (“IPAs”) and offers a cloud-based proprietary technology platform to IPAs which aggregates clinical and claims data across multiple settings, information systems and sources to create a holistic view of patients and providers. We employ approximately 1,500 employees and partner with over 800 physicians. Our corporate headquarters is based in Houston, Texas. We were incorporated on April 13, 2000 in the state of Delaware. Merger of Nutex Health Holdco LLC and Clinigence Holdings, Inc In connection with the Merger Agreement, Nutex Health Holdco LLC entered into certain Contribution Agreements with holders of equity interests (“Nutex Owners”) of subsidiaries and affiliates (the “Nutex Subsidiaries”) pursuant to which such Nutex Owners agreed to contribute certain equity interests in the Nutex Subsidiaries to Nutex Health Holdco LLC in exchange for specified equity interests in Nutex Health Holdco LLC (collectively, the “Contribution Transaction”). Nutex owners having ownership interests representing approximately 84 Pursuant to the Merger Agreement, each unit representing an equity interest in Nutex Health Holdco LLC issued and outstanding immediately prior to the effective time of the Merger but after the Contribution Transaction (collectively, the “Nutex Membership Interests”) was converted into the right to receive 3.571428575 shares of common stock of Clinigence, or an aggregate of 592,791,712 Potential Future Stock Issuances. Such additional shares will be issued at the greater of (a) the price of the Company’s common stock at the time of determination or (b) $2.80. In addition, on the 24-month anniversary of the respective opening dates, contributing owners of under construction hospitals will be eligible to receive such owner’s pro rata share of a number of shares of Company common stock equal to (a)(i) the trailing twelve months earnings before interest, taxes, depreciation and amortization as determined on the 24th anniversary of their respective opening times (ii) ten minus (iii) the aggregate amount of such owner’s capital contribution minus (iv) such owner’s pro rata share of the aggregate debt of the applicable under construction hospital outstanding as of the Closing of the Merger divided by (b) the greater of (i) the price of the Company common stock at the time of determination or (ii) $2.80. After completing the merger, Clinigence was renamed Nutex Health Inc. Lock-up agreements. The lock-up restrictions terminate with respect to one-third of the shares of Company Common Stock issued in connection with the merger immediately following each of (i) six months after the effective time of the merger, (ii) twelve months after the effective time of the merger and (iii) eighteen months after the effective time of the merger. Registration rights agreement. The registration rights agreement terminates on the earlier of (i) the date when there are no shares subject to the agreement or (ii) the dissolution or liquidation of the Company.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 - Summary of Significant Accounting Policies Basis of presentation Business Combinations The assets, including identified intangible assets, and liabilities of Clinigence were recorded at their fair values with the excess purchase price recorded as goodwill. The financial statements reflect the merger as the equivalent of the issuance of common stock for the net monetary assets of Clinigence. The accounting for the merger did not affect the carrying values of the assets and liabilities of Nutex Health Holdco LLC. Equity of the accounting acquirer, Nutex Health Holdco LLC, has been retroactively restated for the equivalent number of shares issued to the accounting acquirer. Similarly, shares outstanding and earnings per share have been also retroactively restated based on the equivalent number of shares issued to the accounting acquirer. These financial statements present the Company’s consolidated financial condition and results of operations including those of majority-owned subsidiaries and variable interest entities (“VIEs”) for which we are the primary beneficiary. The hospital division includes our healthcare billing and collections company and hospital entities. In addition, we have financial and operating relationships with multiple professional entities (the “Physician LLCs”) and real estate entities (the “Real Estate Entities”). The Physician LLCs employ the doctors who work in our hospitals. These entities are consolidated by the Company as VIEs because they do not have significant equity at risk, and we have historically provided support to the Physician LLCs in the event of cash shortages and received the benefit of their cash surpluses. The Real Estate Entities own the land and hospital buildings which are leased to our hospital entities. The consolidated Real Estate Entities have mortgage loans payable to third parties which are collateralized by the land and buildings. The Real Estate Entities are consolidated by the Company as VIEs because they do not have sufficient equity at risk and our hospital entities are guarantors of their outstanding mortgage loans. We have been working with the third-party lenders to remove our guarantees of their outstanding mortgage loans. As these guarantees are released, the associated Real Estate Entity no longer qualifies as a VIE and is deconsolidated. During the second quarter of 2022, we deconsolidated 17 Real Estate Entities. The Company has no direct or indirect ownership interest in the Physician LLCs or Real Estate Entities, so 100 The population health management division includes our management services organizations and a healthcare information technology company providing a cloud-based platform for healthcare organizations. In addition, Associated Hispanic Physicians of So. California (“AHISP”), an IPA entity that is not owned by us, but is consolidated as a VIE of our wholly-owned subsidiary of AHP Management Health Services Inc. (“AHP”) since AHP is the primary beneficiary of its operations and has 100% control of AHISP’s operations through its management services agreement with AHISP. All significant intercompany balances and transactions have been eliminated in consolidation. Interim financial statements Use of estimates Revenue recognition Hospital division Patient service net revenues earned by the Company are recognized at a point in time when the services are provided, net of adjustments and discounts. Because all the Company’s performance obligations relate to contracts with a duration of less than one-year, certain disclosures are limited. The transaction price is determined based on gross charges for services provided, reduced by contractual adjustments provided to third-party payors, discounts and implicit price concessions provided primarily to uninsured patients in accordance with the Company’s policy. For uninsured patients, the Company recognizes revenue based on established rates, subject to certain discounts and implicit price concessions. The Company is reimbursed from third party payors under various methodologies based on the level of care provided. We are considered “out-of-network” with commercial health plans. As there are no contractual rates established with insurance entities, revenues are estimated based on the “usual and customary” charges allowed by insurance payors using historical collection experience, historical trends of refunds and payor payment adjustments (retractions). Revenue from the Medicare program is based on reimbursement rates set by governmental authorities. Patients who have health care insurance may also have discounts applied related to their copayment or deductible. Estimates of contractual adjustments and discounts are determined by major payor classes for outpatient revenues based on historical experience. The Company estimates implicit price concessions based on its historical collection experience with these classes of patients using a portfolio approach. The portfolios consist of major payor classes for outpatient revenue. Based on historical collection trends and other analyses, the Company concluded that revenue for a given portfolio would not be materially different than if accounting for revenue on a contract-by-contract basis. Customer payments are due upon receipt of an explanation of benefits for insured patients or it is due upon receipt of the bill from the Company for uninsured payments. There is no financing component associated with payments due from insurers or patients. Population health management division Capitation revenue consists primarily of capitated fees for medical services provided by physician-owned entities we consolidate as VIEs. Capitated arrangements are made directly with various managed care providers including HMOs. Capitation revenues are typically prepaid monthly to us based on the number of enrollees selecting us as their healthcare provider. Capitation is a fixed payment amount per patient per unit of time paid in advance for the delivery of health care services, whereby the service providers are generally liable for excess medical costs. We receive management fees that are received based on gross capitation revenues of the IPAs or physician groups we manage. Revenue is recognized and received monthly for our services. In addition, we provide consultant services that are charged as a flat fixed rate and recognized as revenue when the service is performed. Consultant services revenues represent a small portion of our total revenue. Software licenses are provided as SaaS-based subscriptions that grants access to proprietary online databases and data management solutions. Training and consulting are project based and billable to customers on a monthly-basis or task-basis. Revenue from training and consulting are generally recognized upon delivery of training or completion of the consulting project. The duration of training and consulting projects are typically a few weeks or months and last no longer than 12 months. SaaS-based subscriptions are generally marketed under multi-year agreements with annual, semi-annual, quarterly, or month-to-month renewals and revenue is recognized ratably over the renewal period with the unearned amounts received recorded as deferred revenue. For multiple-element arrangements accounted for in accordance with specific software accounting guidance, multiple deliverables are segregated into units of accounting which are delivered items that have value to a customer on a standalone basis. Cash payments for SaaS-based subscriptions received in advance of the satisfaction of our performance obligations are reported as deferred revenue and recognized as revenue over the period in which the performance obligations are satisfied. The Company completes its contractual performance obligations through providing its customers access to specified data through subscriptions for a service period, and training on consulting associated with the subscriptions. We primarily invoice our customers on a monthly basis and do not provide any refunds, rights of return, or warranties. Cash and cash equivalents 250,000 Inventories Property and equipment Intangible assets Goodwill Long-lived assets Stock-based compensation The Company uses the Black-Scholes option pricing model to estimate the fair value of its stock options and warrants. The Black-Scholes option pricing model requires the input of highly subjective assumptions including the expected stock price volatility of the Company’s common stock, the risk-free interest rate at the date of grant, the expected vesting term of the grant, expected dividends, and an assumption related to forfeitures of such grants. Changes in these subjective input assumptions can materially affect the fair value estimate of the Company’s stock options and warrants. Leases Convertible instruments The Company accounts for convertible instruments (when it has been determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: The Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption. The Company accounts for the conversion of convertible debt when a conversion option has been bifurcated using the general extinguishment standards. The debt and equity linked derivatives are removed at their carrying amounts and the shares issued are measured at their then-current fair value, with any difference recorded as a gain or loss on extinguishment of the two separate accounting liabilities. Noncontrolling interests Fair value measurements Level 1 — Observable inputs such as quoted prices in active markets for identical assets or liabilities. Level 2 — Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market data. Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs. The estimated fair value of accounts receivable, accounts payable, accrued expenses and notes payable approximate the carrying amount due to the relatively short maturity or time to maturity of these instruments. Accounts receivable and payable with related parties may not be arms-length transactions and therefore, may not reflect fair value. Advertising and marketing expense Income taxes Each of the VIEs and other entities that are not wholly-owned are pass-through entities treated as partnerships for U.S. federal income tax purposes. No provision for federal income taxes is provided in the consolidated statements of operations for the noncontrolling interests associated with these entities. We file tax returns in the U.S. and various state jurisdictions. With few exceptions, our returns for periods prior to 2017 are no longer subject to examination by tax authorities in these jurisdictions. We recognize the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. If a tax position meets the “more likely than not” recognition criteria, accounting guidance requires the tax position be measured at the largest amount of benefit greater than 50% likely of being realized upon ultimate settlement. We record income tax related interest and penalties, if any, as a component in the provision for income tax expense. Earnings (loss) per share Business combinations Segment reporting Variable interest entities The primary beneficiary analysis is a qualitative analysis based on power and economics. The Company consolidates a VIE if both power and benefits belong to the Company – that is, the Company (i) has the power to direct the activities of a VIE that most significantly influence the VIE’s economic performance (power), and (ii) has the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE (benefits). The Company consolidates VIEs whenever it is determined that the Company is the primary beneficiary. Refer to Note 18 – “Variable Interest Entities (VIEs)” to the consolidated financial statements for information on the Company’s consolidated VIEs. If there are variable interests in a VIE but the Company is not the primary beneficiary, the Company may account for the investment using the equity method of accounting. Reclassifications Recent accounting pronouncements

Merger of Nutex Health Holdco L

Merger of Nutex Health Holdco LLC and Clinigence Holdings, Inc	6 Months Ended
	Jun. 30, 2022
Business Combination and Asset Acquisition [Abstract]
Merger of Nutex Health Holdco LLC and Clinigence Holdings, Inc	Note 3 - Merger of Nutex Health Holdco LLC and Clinigence Holdings, Inc The merger of Nutex Health Holdco LLC and Clinigence was completed pursuant to the Merger Agreement on April 1, 2022. As discussed above, the merger was accounted for as a reverse business combination with Nutex Health Holdco LLC as the accounting acquirer and Clinigence as the accounting acquiree. The fair value of purchase consideration transferred on the closing date includes the value of the shares of the combined company owned by Clinigence shareholders at closing of the merger and the fair value of Clinigence’s outstanding and exercisable common stock options and warrants as determined using a Black-Scholes valuation model. The fair value per share of Clinigence’s common stock was $6.40; its traded closing price on April 1, 2022. Total consideration in the merger is shown below: Schedule of consideration Fair value of Clinigence common shares at $6.40 per share $ 326,151,098 Fair value of Clinigence outstanding common stock options and warrants 120,875,452 Total consideration $ 447,026,550 The following is a preliminary estimate of the allocation of the total purchase consideration to acquired assets and assumed liabilities including the fair value of identified intangible assets as determined by independent valuation (a level 3 measurement): Schedule of acquired assets and assumed liabilities Cash and cash equivalents $ 12,716,228 Accounts receivable, net 2,127,076 Prepaid expenses and other current assets 127,384 Property and equipment, net 14,793 Right of use asset, net 86,989 Intangible assets, net 21,668,000 Goodwill 424,216,539 Accounts payable and accrued expenses (3,966,100 ) Deferred revenue (92,111 ) Convertible notes payable, net (3,771,858 ) Term note payable (553,150 ) Lease liability (91,238 ) Deferred tax liability (5,456,002 ) Assets acquired $ 447,026,550 The intangible assets denoted above each have definite lives. These intangible assets are being amortized over their estimated useful lives of 5 16 The results of operations of Clinigence have been included in the Company’s consolidated financial statements since the April 1, 2022 merger date. We expensed $ 3.9 Supplemental Pro Forma Information The supplemental pro forma financial information reflects pro forma adjustments to present the combined pro forma results of operations as if the acquisition had occurred on January 1, 2021, to give effect to certain events that management believes to be directly attributable to the acquisition. These pro forma adjustments primarily include an increase to depreciation and amortization expense that would have been recognized due to acquired tangible and intangible assets. The supplemental pro forma financial information for the periods presented is as follows: Schedule of pro forma financial information Three months ended June 30 Six months ended June 30 2022 2021 2022 2021 Revenue $ 58,047,933 $ 68,105,177 $ 143,384,350 $ 157,462,764 Net income (loss) attributable to Nutex Health Inc. (19,395,754) 23,711,523 (12,215,600) 56,629,242 The pro forma adjustment included in the pro forma loss above for the six months ended June 30, 2022 included $ 14.2

Revenue

Revenue	6 Months Ended
	Jun. 30, 2022
Revenue from Contract with Customer [Abstract]
Revenue	Note 4 – Revenue We disaggregate revenue from contracts with customers into types of services or products, consistent with our reportable segments, as follows: Schedule of disaggregate revenue Three months ended June 30 Six months ended June 30 2022 2021 2022 2021 Hospital Division: Net patient service revenue $ 51,209,741 $ 62,347,436 $ 130,025,739 $ 149,260,934 Management fees 394,938 467,236 706,182 896,980 Total Hospital Division revenue 51,604,679 62,814,672 130,731,921 150,157,914 Population Health Management Division: Capitation revenue, net 5,150,342 — 5,150,342 — SaaS revenue 290,112 — 290,112 — Management fees 1,002,800 — 1,002,800 — Total Population Health Management Division revenue 6,443,254 — 6,443,254 — Net revenue $ 58,047,933 $ 62,814,672 $ 137,175,175 $ 150,157,914 Net patient service revenue Schedule of allocation of the estimated transaction price Three months ended June 30 Six months ended June 30 2022 2021 2022 2021 Insurance 92 % 97 % 92 % 96 % Self pay 8 % 2 % 8 % 3 % Workers compensation 0 % 1 % 0 % 1 % Medicare/Medicaid 0 % 0 % 0 % 0 % Total 100 % 100 % 100 % 100 % Contract balances 55,355 0

Property and Equipment

Property and Equipment	6 Months Ended
	Jun. 30, 2022
Property, Plant and Equipment [Abstract]
Property and Equipment	Note 5 - Property and Equipment The principal categories of property and equipment are summarized as follows: Schedule of property, plant and equipment Useful lives (yrs) June 30, 2022 December 31, 2021 Buildings and improvements 39 $ 8,572,428 $ 82,794,329 Land — 1,972,509 18,201,804 Leasehold improvements 10 39 28,776,436 27,038,503 Construction in progress — 7,606,103 4,299,614 Medical equipment 10 26,284,999 25,686,562 Office furniture and equipment 7 2,864,410 2,870,270 Computer hardware and software 5 1,611,434 1,288,224 Vehicles 5 135,590 161,590 Signage 10 1,164,377 1,160,195 Total cost 78,988,286 163,501,091 Less: accumulated depreciation 11,165,604 11,588,591 Total property and equipment, net $ 67,822,682 $ 151,912,500 In the second quarter of 2022, we deconsolidated 17 Real Estate Entities. Refer to note 18.

Intangible Assets

Intangible Assets	6 Months Ended
	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Note 6 – Intangible Assets The following tables provide detail of the Company’s intangible assets: Schedule of intangible assets As of June 30, 2022 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Weighted Average Useful Life (in years) Amortized intangible assets: Member relationships $ 16,899,000 $ (281,649 ) $ 16,617,351 15 Management contracts 2,021,000 (31,578 ) 1,989,422 16 Customer contracts 914,000 (15,234 ) 898,766 15 Trademarks 1,425,000 (37,508 ) 1,387,492 7 12 PHP technology 409,000 (20,450 ) 388,550 5 Indefinite life intangible - license 682,649 — 682,649 — Total $ 22,350,649 $ (386,419 ) $ 21,964,230 As of December 31, 2021 Indefinite life intangible - license $ 682,649 $ — $ 682,649 — Amortization expense for the three months ended June 30, 2022 and 2021 totaled $ 386,419 0 386,419 0

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	6 Months Ended
	Jun. 30, 2022
Payables and Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	Note 7 – Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following: Schedule of accrued expenses and other current liabilities June 30, 2022 December 31, 2021 Accrued wages and benefits $ 5,470,145 $ 3,088,264 Current taxes payable 7,595,105 — Accrued other 4,126,010 3,776,162 Total accrued expenses and other current liabilities $ 17,191,260 $ 6,864,426

Debt

Debt	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Debt	Note 8 – Debt The Company’s outstanding debt is shown in the following table: Schedule of debt Maturity dates Interest rates June 30, 2022 December 31, 2021 Term loans secured by all assets 04/2023 - 11/2030 3.25 6.00 $ 10,728,901 $ 15,613,564 Term loans secured by property and equipment 01/2024 - 10/2029 4.19 6.90 7,049,839 11,190,093 Line of credit secured by all assets 07/2022 - 01/2023 4.50 6.50 2,592,714 72,055 Notes payable convertible into Nutex common shares at $1.55 per share 07/2022 10.00 % 342,963 — Term loans of consolidated Real Estate Entities 08/2022 - 12/2040 2.84 5.75 6,020,949 62,478,951 Total 26,735,366 89,354,663 Less: unamortized debt issuance costs 101,634 301,691 Less: short-term lines of credit 2,592,714 72,055 Less: current portion of long-term debt 7,735,760 10,158,932 Total debt reflected as long-term $ 16,305,258 $ 78,821,985 Term loans and lines of credit Certain outstanding debt arrangements require minimum debt service coverage ratios and other financial covenants. A revolving line of credit was not in compliance with the debt service coverage ratio as of June 30, 2022, and the balance has been included in current liabilities. At June 30, 2022, we had remaining availability of $ 1.657 Convertible notes payable. 5,415,375 4,065,375 2,622,819 342,963 The convertible notes payable were fully converted to common stock before their maturity on July 31, 2022

Leases

Leases	6 Months Ended
	Jun. 30, 2022
Leases [Abstract]
Leases	Note 9 – Leases The hospital facilities have entered into hospital property and equipment rental agreements with various lessors. The hospital facilities (“ER Entities”) have related party lease agreements with consolidated Real Estate Entities, which are eliminated and not shown in the tables below. Nutex has provided a corporate guarantee of these leases. Other facility leases with related parties are presented in our consolidated balance sheets and shown below when the associated Real Estate Entity is not consolidated. Third party leases include hospital facilities and medical equipment leases. The discount rate used in determining the present value of lease payment at commencement was 5% and 15%, respectively, for building and equipment leases. The following tables disclose information about our leases of property and equipment: Schedule of lease of property and equipment Three months ended June 30 Six months ended June 30 2022 2021 2022 2021 Operating lease cost $ 862,642 $ 662,104 $ 1,555,311 $ 1,013,461 Finance lease cost: Amortization of right-of-use assets 3,539,969 572,052 4,467,633 1,129,023 Interest on lease liabilities 3,770,058 503,968 4,750,677 1,002,396 Total finance lease cost $ 7,310,027 $ 1,076,020 $ 9,218,310 $ 2,131,419 Schedule of minimum lease payments Operating Leases Finance Leases Minimum lease payments for the next five years: Third-parties Related parties Third-parties Related parties 2022 $ 1,020,472 $ 298,260 $ 1,193,459 $ 5,666,492 2023 2,065,162 604,631 2,450,062 11,450,611 2024 2,086,611 627,080 2,129,408 11,703,516 2025 2,136,809 638,490 1,905,419 11,873,566 2026 2,035,479 662,159 1,949,506 12,049,752 2027 2,026,407 674,251 1,994,625 12,227,137 Thereafter 8,350,671 5,171,218 33,997,249 221,826,195 Total minimum lease payments 19,721,611 8,676,089 45,619,728 286,797,269 Less interest (1,722,511 ) (2,348,744 ) (17,644,332 ) (118,583,875 ) Total lease liabilities $ 17,999,100 $ 6,327,345 $ 27,975,396 $ 168,213,394

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 10 – Commitments and Contingencies Litigation

Employee Benefit Plans

Employee Benefit Plans	6 Months Ended
	Jun. 30, 2022
Retirement Benefits [Abstract]
Employee Benefit Plans	Note 11 – Employee Benefit Plans The Company’s employees are eligible to participate in the 401(k) Savings Plan. There are no restrictions in eligibility to contribute to the 401(k) Savings Plan. Salary deferrals are allowed in amounts up to 100% of an eligible employee’s salary, not to exceed the maximum allowed by law. Texarkana Emergency Center & Hospital, LLC (“Texarkana”) is the only entity which may contribute a discretionary match up to 5 no

Stock-based Compensation

Stock-based Compensation	6 Months Ended
	Jun. 30, 2022
Equity [Abstract]
Stock-based Compensation	Note 12 – Stock-based Compensation Obligations for under-development and ramping hospitals. th Restricted stock Options Clinigence had 6,500,010 options for the purchase of our common stock outstanding as of the merger date, all of which were fully vested and exercisable. The following table summarizes stock-based awards activity: Schedule of stock option activities Weighted Average Options Weighted Remaining Contractual Outstanding Average Life (Years) Options outstanding at April 1, 2022 merger date 6,500,010 $ 2.30 6.62 Options exercised (312,019 ) 2.08 Options outstanding at June 30, 2022 6,187,991 $ 2.30 6.17 Options outstanding as of June 30, 2022 consist of: Schedule of stock options outstanding Expiration Number Number Exercise Date Outstanding Exercisable Price March 15, 2025 157,196 157,196 $ 2.00 January 27, 2027 180,000 180,000 1.50 May 11, 2027 350,000 350,000 1.50 June 6, 2027 3,600 3,600 0.07 August 16, 2027 25,000 25,000 2.51 September 7, 2027 2,975,000 2,975,000 2.75 September 27, 2027 410,000 410,000 2.75 December 17, 2027 157,000 157,000 3.50 January 28, 2028 180,000 180,000 1.61 January 27, 2030 296,865 296,865 1.50 February 28, 2030 95,794 95,794 1.25 June 30, 2030 117,056 117,056 1.45 August 5, 2029 40,480 40,480 5.56 January 28, 2031 1,000,000 1,000,000 1.61 February 25, 2031 200,000 200,000 2.00 Total 6,187,991 6,187,991 Warrants. Schedule of Warrants, Activity Warrants Weighted Average Average Remaining Contractual Life Outstanding Exercise Price (Years) Warrants outstanding at April 1, 2022 merger date 12,401,240 $ 2.04 4.65 Warrants exercised (2,187,225 ) 2.27 Warrants outstanding at June 30, 2022 10,214,015 $ 2.04 4.60 Warrants outstanding as of June 30, 2022 consisted of: Schedule of outstanding warrants Expiration Number Number Exercise Date Outstanding Exercisable Price February 5, 2023 1,500 1,500 $ 25.00 April 27, 2023 1,500 1,500 25.00 December 31, 2024 554,873 554,873 6.67 October 31, 2025 763,701 763,701 1.25 February 26, 2026 288,236 288,236 4.00 July 31, 2026 2,532,900 2,532,900 1.55 February 1, 2027 1,456,452 1,456,452 1.55 May 30, 2027 4,614,853 4,614,853 1.75 Total 10,214,015 10,214,015

Equity

Equity	6 Months Ended
	Jun. 30, 2022
Equity [Abstract]
Equity	Note 13 – Equity Common Stock Issued 4,065,375 2,622,819 In the second quarter of 2022, we issued 2,147,252 4,119,141 312,019 644,974

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Note 14 – Income Taxes Income tax provisions for interim quarterly periods are generally based on an estimated annual effective income tax rate calculated separately from the effect of significant, infrequent or unusual items related specifically to interim periods. The income tax impact of discrete items are recognized in the period these occur. The Company’s income tax expense for the periods presented and reconciliation of this amount to amounts calculated based on statutory tax rates follows: Schedule of income tax expense Three months ended June 30 Six months ended June 30 2022 2021 2022 2021 Income taxes computed at the federal statutory rate $ (803,226 ) $ 6,333,505 $ 4,447,290 $ 17,051,034 Effect of: State taxes, net of federal benefits 675,275 481,501 675,275 638,354 Income of flow-through entities 238,172 (6,333,505 ) (4,836,021 ) (17,051,034 ) Change in tax status of Nutex Health Holdco LLC 20,775,898 — 20,775,898 — Reversal of acquired Clinigence valuation allowance (2,393,178 ) — (2,393,178 ) — Other permanent items, net 1,160,345 — 1,160,345 — Total income tax expense $ 19,653,286 $ 481,501 $ 19,829,609 $ 638,354 In periods before the merger with Clinigence, Nutex Health Holdco LLC and the Nutex Subsidiaries were pass-through entities treated as partnerships for U.S. federal income tax purposes. No provision for federal income taxes was provided for these periods as federal taxes were obligations of these companies’ members. After the merger, Nutex Health Holdco LLC became a wholly-owned subsidiary of Clinigence and will be included in its future consolidated corporate tax filings. We recognized a non-cash charge of $ 20,775,898 At the time of our merger with Clinigence, Clinigence had a full valuation allowance against its deferred tax assets. During the three months ended June 30, 2022, we recorded a non-cash benefit of $ 2,393,178 Each of the discrete items above are one-time, non-cash items. Excluding the discrete items above, our effective tax rate for the three months ended June 30, 2022 was 25.2

Earnings per Share

Earnings per Share	6 Months Ended
	Jun. 30, 2022
Earnings (loss) per common share
Earnings per Share	Note 15 – Earnings per Share The following is the computation of earnings (loss) per basic and diluted share: Schedule of earnings per share Three months ended June 30 Six months ended June 30 2022 2021 2022 2021 Amounts attributable to Nutex Health Inc.: Numerator- Net income (loss) attributable to common stockholders $ (19,395,752 ) $ 27,059,401 $ 2,134,550 $ 64,821,537 Denominator: Weighted average shares used to compute basic EPS 646,370,173 592,791,712 619,728,949 592,791,712 Dilutive effect of convertible note 851,611 — 851,611 — Dilutive effect of common stock options 4,296,239 — 2,285,171 — Dilutive effect of common stock warrants 7,473,169 — 4,127,086 — Weighted average shares used to compute diluted EPS 658,991,192 592,791,712 626,992,817 592,791,712 Earnings (loss) per share: Basic $ (0.03 ) $ 0.05 $ 0.00 $ 0.11 Diluted $ (0.03 ) $ 0.05 $ 0.00 $ 0.11 The computation of diluted earnings per common share excludes the assumed conversion of outstanding convertible notes and exercise of common stock options and warrants in periods when we report a loss. The dilutive effect of the assumed exercise of outstanding options and warrants was calculated using the treasury stock method.

Segment Information

Segment Information	6 Months Ended
	Jun. 30, 2022
Segment Reporting [Abstract]
Segment Information	Note 16 – Segment Information We report the results of our operations as three segments in our consolidated financial statements: (i) the hospital division, (ii) the population health management division and (ii) the real estate division. The determination of our reporting segments was made on the basis of our strategic priorities, which corresponds to the manner in which our Chief Executive Officer, as our chief operating decision maker, reviews and evaluates operating performance to make decisions about resources to be allocated. We evaluate the performance of our reportable segments based on, among other measures, operating income, which is defined as income before interest expense, other income (expense), and taxes. Corporate costs primarily include expenses for support functions and salaries and benefits for corporate employees and are excluded from segment operating results. Reportable segment information, including intercompany transactions, is presented below: Schedule of segment information Three months ended June 30 Six months ended June 30 2022 2021 2022 2021 Revenues from external customers Hospital division $ 51,604,679 $ 62,814,672 $ 130,731,921 $ 150,157,914 Population health management division 6,443,254 — 6,443,254 — Total revenue 58,047,933 62,814,672 137,175,175 150,157,914 Segment operating income: Hospital division 5,249,528 29,137,332 39,647,506 83,787,175 Population health management division (257,002 ) — (257,002 ) — Total segment operating income $ 4,992,526 $ 29,137,332 $ 39,390,504 $ 83,787,175 Capital expenditures: Hospital division $ 1,364,694 $ 5,751,861 $ 3,730,053 $ 6,233,817 Real estate division 6,665,209 4,798,142 12,891,673 15,480,938 Total capital expenditures $ 8,029,903 $ 10,550,003 $ 16,621,726 $ 21,714,755 Revenue from inter-segment activities: Real estate division $ 7,943,243 $ — $ 11,989,212 $ 11,054,153 Depreciation and amortization: Hospital division $ 2,703,655 $ 1,381,394 $ 5,096,326 $ 3,155,383 Population health management division 387,984 — 387,984 — Real estate division 40,846 842,067 45,036 846,257 Total depreciation and amortization $ 3,132,485 $ 2,223,461 $ 5,529,346 $ 4,001,640 Schedule of assets As of June 30, 2022 December 31, 2021 Assets: Hospital division $ 384,426,690 $ 287,316,356 Population health management division 462,484,616 — Real estate division 24,881,954 107,333,687 Total Assets $ 871,793,260 $ 394,650,043

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2022
Related Party Transactions [Abstract]
Related Party Transactions	Note 17 – Related Party Transactions Related party transactions included the following: • The Physician LLCs employ the doctors who work in our hospitals. We have no direct ownership interest in these entities but they are owned and, in some instances, controlled by related parties including our CEO, Dr. Thomas Vo. The Physician LLCs are consolidated by the Company as VIEs because they do not have significant equity at risk, and we have historically provided support to them in the event of cash shortages and received the benefit of their cash surpluses. Amounts due from Physician LLCs totaled $ 2,783,241 1,891,147 1,506,650 No The Physician LLCs had outstanding obligations to their member owners, who are also Company stockholders, totaling $ 2,058,701 2,675,195 • Most of our hospital division facilities are leased from Real Estate Entities which own the land and hospital buildings. These leases are typically on a triple net basis where our hospital division is responsible for all operating costs, repairs and taxes on the facilities. Our obligations under these leases are presented in Note 9. During the three and six months ended June 30, 2022, we made cash payments for these lease obligations totaling $ 3,305,798 6,189,479 2,707,276 5,373,106 We received $ 1,245,000 The consolidated Real Estate Entities have mortgage loans payable to third parties which are collateralized by the land and buildings. We have no direct ownership interest in these entities but they are owned and, in some instances, controlled by related parties including our CEO. The Real Estate Entities are consolidated by the Company as VIEs when they do not have sufficient equity at risk and our hospital entities are guarantors of their outstanding mortgage loans. We have been working with the third-party lenders to remove our guarantees of their outstanding mortgage loans. As these guarantees are released, the associated Real Estate Entity no longer qualifies as a VIE and is deconsolidated. During the second quarter of 2022, we deconsolidated 17 Real Estate Entities. At June 30, 2022, three Real Estate Entities continue to be consolidated in our financial statements. In connection with the merger with Clinigence, we forgave certain amounts due from Real Estate Entities for past advances made by us. We recognized net expense totaling $ 0 553,259 • We made advances to unconsolidated entities owned by related parties that we lease facilities from. These advances totaled $ 1,228,442 1,288,354 • Accounts receivable – related party included $ 162,607 600,044 • Our CEO made advances to one of our hospital facilities, SE Texas ER. These advances totaled $ 1,424,948 • Accounts payable – related party in our consolidated balance sheets included $ 130,676 0 • We provide managerial services to emergency centers owned and, in some instances, controlled by related parties including our CEO. We recognized $ 188,417 600,971 226,532 874,440 • Two of our ER Entities, Coppell and West Plano, are obligated under managerial services agreements with related parties commencing in 2022. Payments under these agreements totaled $ 1,235,486 1,558,680

Variable Interest Entities

Variable Interest Entities	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Variable Interest Entities	Note 18 – Variable Interest Entities The following tables provide the balance sheet amounts for consolidated VIEs: Schedule of consolidated balance sheets June 30, 2022 Real Estate Physician AHP Entities LLCs IPA Current assets $ 15,991,847 $ 14,599,965 $ 25,116,483 Property and equipment, net 8,865,609 3,668 — Other long-term assets 24,500 — 17,150,197 Total assets $ 24,881,956 $ 14,603,633 $ 42,266,680 Current liabilities 2,226,930 8,584,407 2,738,537 Long-term liabilities 6,020,950 — — Total liabilities 8,247,880 8,584,407 2,738,537 Equity 16,634,076 6,019,226 39,528,143 Total liabilities and equity $ 24,881,956 $ 14,603,633 $ 42,266,680 December 31, 2021 Real Estate Physician Entities LLCs Current assets $ 10,959,090 $ 22,035,457 Property and equipment, net 32,182,902 — Long-term assets 128,870,699 4,279 Total assets $ 172,012,691 $ 22,039,736 Current liabilities 6,666,690 5,070,706 Long-term liabilities 68,850,689 930,000 Total liabilities 75,517,379 6,000,706 Equity 96,495,312 16,039,030 Total liabilities and equity $ 172,012,691 $ 22,039,736 The assets of each of the ER Entities may only be used to settle the liabilities of that entity or its consolidated VIEs and may not be required to be used to settle the liabilities of any of the other ER Entities, other VIEs, or corporate entity. Additionally, the assets of corporate entities cannot be used to settle the liabilities of VIEs. The Company has aggregated all of the Physician LLCs and Real Estate Entities into two categories above, because they have similar risk characteristics, and presenting distinct financial information for each VIE would not add more useful information. Real Estate Entities are consolidated by the Company as VIEs because they do not have sufficient equity at risk and our hospital entities are guarantors of their outstanding mortgage loans. We have been working with the third-party lenders to remove our guarantees of their outstanding mortgage loans. As these guarantees are released, the associated Real Estate Entity no longer qualifies as a VIE and is deconsolidated. In the second quarter of 2022, we deconsolidated 17 Real Estate Entities. There was no gain or loss on the deconsolidation of these entities. At the date we deconsolidated these Real Estate Entities, they had $ 2,421,212 98,086,690 533,874 69,638,778 1,402,998 ur condensed consolidated statements of changes in equity includes an additional equity effect of $7,920,874 in the Deconsolidation of Real Estate Entities total of $ 39,323,872

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	Note 19 - Subsequent Events The Company has evaluated subsequent events through the filing of this report and determined that there have been no events that have occurred that would require adjustments to our disclosures in the consolidated financial statements except for the transaction described below. Since June 30, 2022 through the date of the report, the remaining principal of convertible notes payable was converted to 851,611 1.55

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Basis of presentation	Basis of presentation Business Combinations The assets, including identified intangible assets, and liabilities of Clinigence were recorded at their fair values with the excess purchase price recorded as goodwill. The financial statements reflect the merger as the equivalent of the issuance of common stock for the net monetary assets of Clinigence. The accounting for the merger did not affect the carrying values of the assets and liabilities of Nutex Health Holdco LLC. Equity of the accounting acquirer, Nutex Health Holdco LLC, has been retroactively restated for the equivalent number of shares issued to the accounting acquirer. Similarly, shares outstanding and earnings per share have been also retroactively restated based on the equivalent number of shares issued to the accounting acquirer. These financial statements present the Company’s consolidated financial condition and results of operations including those of majority-owned subsidiaries and variable interest entities (“VIEs”) for which we are the primary beneficiary. The hospital division includes our healthcare billing and collections company and hospital entities. In addition, we have financial and operating relationships with multiple professional entities (the “Physician LLCs”) and real estate entities (the “Real Estate Entities”). The Physician LLCs employ the doctors who work in our hospitals. These entities are consolidated by the Company as VIEs because they do not have significant equity at risk, and we have historically provided support to the Physician LLCs in the event of cash shortages and received the benefit of their cash surpluses. The Real Estate Entities own the land and hospital buildings which are leased to our hospital entities. The consolidated Real Estate Entities have mortgage loans payable to third parties which are collateralized by the land and buildings. The Real Estate Entities are consolidated by the Company as VIEs because they do not have sufficient equity at risk and our hospital entities are guarantors of their outstanding mortgage loans. We have been working with the third-party lenders to remove our guarantees of their outstanding mortgage loans. As these guarantees are released, the associated Real Estate Entity no longer qualifies as a VIE and is deconsolidated. During the second quarter of 2022, we deconsolidated 17 Real Estate Entities. The Company has no direct or indirect ownership interest in the Physician LLCs or Real Estate Entities, so 100 The population health management division includes our management services organizations and a healthcare information technology company providing a cloud-based platform for healthcare organizations. In addition, Associated Hispanic Physicians of So. California (“AHISP”), an IPA entity that is not owned by us, but is consolidated as a VIE of our wholly-owned subsidiary of AHP Management Health Services Inc. (“AHP”) since AHP is the primary beneficiary of its operations and has 100% control of AHISP’s operations through its management services agreement with AHISP. All significant intercompany balances and transactions have been eliminated in consolidation.
Interim financial statements	Interim financial statements
Use of estimates	Use of estimates
Revenue recognition	Revenue recognition Hospital division Patient service net revenues earned by the Company are recognized at a point in time when the services are provided, net of adjustments and discounts. Because all the Company’s performance obligations relate to contracts with a duration of less than one-year, certain disclosures are limited. The transaction price is determined based on gross charges for services provided, reduced by contractual adjustments provided to third-party payors, discounts and implicit price concessions provided primarily to uninsured patients in accordance with the Company’s policy. For uninsured patients, the Company recognizes revenue based on established rates, subject to certain discounts and implicit price concessions. The Company is reimbursed from third party payors under various methodologies based on the level of care provided. We are considered “out-of-network” with commercial health plans. As there are no contractual rates established with insurance entities, revenues are estimated based on the “usual and customary” charges allowed by insurance payors using historical collection experience, historical trends of refunds and payor payment adjustments (retractions). Revenue from the Medicare program is based on reimbursement rates set by governmental authorities. Patients who have health care insurance may also have discounts applied related to their copayment or deductible. Estimates of contractual adjustments and discounts are determined by major payor classes for outpatient revenues based on historical experience. The Company estimates implicit price concessions based on its historical collection experience with these classes of patients using a portfolio approach. The portfolios consist of major payor classes for outpatient revenue. Based on historical collection trends and other analyses, the Company concluded that revenue for a given portfolio would not be materially different than if accounting for revenue on a contract-by-contract basis. Customer payments are due upon receipt of an explanation of benefits for insured patients or it is due upon receipt of the bill from the Company for uninsured payments. There is no financing component associated with payments due from insurers or patients. Population health management division Capitation revenue consists primarily of capitated fees for medical services provided by physician-owned entities we consolidate as VIEs. Capitated arrangements are made directly with various managed care providers including HMOs. Capitation revenues are typically prepaid monthly to us based on the number of enrollees selecting us as their healthcare provider. Capitation is a fixed payment amount per patient per unit of time paid in advance for the delivery of health care services, whereby the service providers are generally liable for excess medical costs. We receive management fees that are received based on gross capitation revenues of the IPAs or physician groups we manage. Revenue is recognized and received monthly for our services. In addition, we provide consultant services that are charged as a flat fixed rate and recognized as revenue when the service is performed. Consultant services revenues represent a small portion of our total revenue. Software licenses are provided as SaaS-based subscriptions that grants access to proprietary online databases and data management solutions. Training and consulting are project based and billable to customers on a monthly-basis or task-basis. Revenue from training and consulting are generally recognized upon delivery of training or completion of the consulting project. The duration of training and consulting projects are typically a few weeks or months and last no longer than 12 months. SaaS-based subscriptions are generally marketed under multi-year agreements with annual, semi-annual, quarterly, or month-to-month renewals and revenue is recognized ratably over the renewal period with the unearned amounts received recorded as deferred revenue. For multiple-element arrangements accounted for in accordance with specific software accounting guidance, multiple deliverables are segregated into units of accounting which are delivered items that have value to a customer on a standalone basis. Cash payments for SaaS-based subscriptions received in advance of the satisfaction of our performance obligations are reported as deferred revenue and recognized as revenue over the period in which the performance obligations are satisfied. The Company completes its contractual performance obligations through providing its customers access to specified data through subscriptions for a service period, and training on consulting associated with the subscriptions. We primarily invoice our customers on a monthly basis and do not provide any refunds, rights of return, or warranties.
Cash and cash equivalents	Cash and cash equivalents 250,000
Inventories	Inventories
Property and equipment	Property and equipment
Intangible assets	Intangible assets
Goodwill	Goodwill
Long-lived assets	Long-lived assets
Stock-based compensation	Stock-based compensation The Company uses the Black-Scholes option pricing model to estimate the fair value of its stock options and warrants. The Black-Scholes option pricing model requires the input of highly subjective assumptions including the expected stock price volatility of the Company’s common stock, the risk-free interest rate at the date of grant, the expected vesting term of the grant, expected dividends, and an assumption related to forfeitures of such grants. Changes in these subjective input assumptions can materially affect the fair value estimate of the Company’s stock options and warrants.
Leases	Leases
Convertible instruments	Convertible instruments The Company accounts for convertible instruments (when it has been determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: The Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption. The Company accounts for the conversion of convertible debt when a conversion option has been bifurcated using the general extinguishment standards. The debt and equity linked derivatives are removed at their carrying amounts and the shares issued are measured at their then-current fair value, with any difference recorded as a gain or loss on extinguishment of the two separate accounting liabilities.
Noncontrolling interests	Noncontrolling interests
Fair value measurements	Fair value measurements Level 1 — Observable inputs such as quoted prices in active markets for identical assets or liabilities. Level 2 — Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market data. Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs. The estimated fair value of accounts receivable, accounts payable, accrued expenses and notes payable approximate the carrying amount due to the relatively short maturity or time to maturity of these instruments. Accounts receivable and payable with related parties may not be arms-length transactions and therefore, may not reflect fair value.
Advertising and marketing expense	Advertising and marketing expense
Income taxes	Income taxes Each of the VIEs and other entities that are not wholly-owned are pass-through entities treated as partnerships for U.S. federal income tax purposes. No provision for federal income taxes is provided in the consolidated statements of operations for the noncontrolling interests associated with these entities. We file tax returns in the U.S. and various state jurisdictions. With few exceptions, our returns for periods prior to 2017 are no longer subject to examination by tax authorities in these jurisdictions. We recognize the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. If a tax position meets the “more likely than not” recognition criteria, accounting guidance requires the tax position be measured at the largest amount of benefit greater than 50% likely of being realized upon ultimate settlement. We record income tax related interest and penalties, if any, as a component in the provision for income tax expense.
Earnings (loss) per share	Earnings (loss) per share
Business combinations	Business combinations
Segment reporting	Segment reporting
Variable interest entities	Variable interest entities The primary beneficiary analysis is a qualitative analysis based on power and economics. The Company consolidates a VIE if both power and benefits belong to the Company – that is, the Company (i) has the power to direct the activities of a VIE that most significantly influence the VIE’s economic performance (power), and (ii) has the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE (benefits). The Company consolidates VIEs whenever it is determined that the Company is the primary beneficiary. Refer to Note 18 – “Variable Interest Entities (VIEs)” to the consolidated financial statements for information on the Company’s consolidated VIEs. If there are variable interests in a VIE but the Company is not the primary beneficiary, the Company may account for the investment using the equity method of accounting.
Reclassifications	Reclassifications
Recent accounting pronouncements	Recent accounting pronouncements

Merger of Nutex Health Holdco_2

Merger of Nutex Health Holdco LLC and Clinigence Holdings, Inc (Tables)	6 Months Ended
	Jun. 30, 2022
Business Combination and Asset Acquisition [Abstract]
Schedule of consideration	Schedule of consideration Fair value of Clinigence common shares at $6.40 per share $ 326,151,098 Fair value of Clinigence outstanding common stock options and warrants 120,875,452 Total consideration $ 447,026,550
Schedule of acquired assets and assumed liabilities	Schedule of acquired assets and assumed liabilities Cash and cash equivalents $ 12,716,228 Accounts receivable, net 2,127,076 Prepaid expenses and other current assets 127,384 Property and equipment, net 14,793 Right of use asset, net 86,989 Intangible assets, net 21,668,000 Goodwill 424,216,539 Accounts payable and accrued expenses (3,966,100 ) Deferred revenue (92,111 ) Convertible notes payable, net (3,771,858 ) Term note payable (553,150 ) Lease liability (91,238 ) Deferred tax liability (5,456,002 ) Assets acquired $ 447,026,550
Schedule of pro forma financial information	Schedule of pro forma financial information Three months ended June 30 Six months ended June 30 2022 2021 2022 2021 Revenue $ 58,047,933 $ 68,105,177 $ 143,384,350 $ 157,462,764 Net income (loss) attributable to Nutex Health Inc. (19,395,754) 23,711,523 (12,215,600) 56,629,242

Revenue (Tables)

Revenue (Tables)	6 Months Ended
	Jun. 30, 2022
Revenue from Contract with Customer [Abstract]
Schedule of disaggregate revenue	Schedule of disaggregate revenue Three months ended June 30 Six months ended June 30 2022 2021 2022 2021 Hospital Division: Net patient service revenue $ 51,209,741 $ 62,347,436 $ 130,025,739 $ 149,260,934 Management fees 394,938 467,236 706,182 896,980 Total Hospital Division revenue 51,604,679 62,814,672 130,731,921 150,157,914 Population Health Management Division: Capitation revenue, net 5,150,342 — 5,150,342 — SaaS revenue 290,112 — 290,112 — Management fees 1,002,800 — 1,002,800 — Total Population Health Management Division revenue 6,443,254 — 6,443,254 — Net revenue $ 58,047,933 $ 62,814,672 $ 137,175,175 $ 150,157,914
Schedule of allocation of the estimated transaction price	Schedule of allocation of the estimated transaction price Three months ended June 30 Six months ended June 30 2022 2021 2022 2021 Insurance 92 % 97 % 92 % 96 % Self pay 8 % 2 % 8 % 3 % Workers compensation 0 % 1 % 0 % 1 % Medicare/Medicaid 0 % 0 % 0 % 0 % Total 100 % 100 % 100 % 100 %

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2022
Property, Plant and Equipment [Abstract]
Schedule of property, plant and equipment	Schedule of property, plant and equipment Useful lives (yrs) June 30, 2022 December 31, 2021 Buildings and improvements 39 $ 8,572,428 $ 82,794,329 Land — 1,972,509 18,201,804 Leasehold improvements 10 39 28,776,436 27,038,503 Construction in progress — 7,606,103 4,299,614 Medical equipment 10 26,284,999 25,686,562 Office furniture and equipment 7 2,864,410 2,870,270 Computer hardware and software 5 1,611,434 1,288,224 Vehicles 5 135,590 161,590 Signage 10 1,164,377 1,160,195 Total cost 78,988,286 163,501,091 Less: accumulated depreciation 11,165,604 11,588,591 Total property and equipment, net $ 67,822,682 $ 151,912,500

Intangible Assets (Tables)

Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of intangible assets	Schedule of intangible assets As of June 30, 2022 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Weighted Average Useful Life (in years) Amortized intangible assets: Member relationships $ 16,899,000 $ (281,649 ) $ 16,617,351 15 Management contracts 2,021,000 (31,578 ) 1,989,422 16 Customer contracts 914,000 (15,234 ) 898,766 15 Trademarks 1,425,000 (37,508 ) 1,387,492 7 12 PHP technology 409,000 (20,450 ) 388,550 5 Indefinite life intangible - license 682,649 — 682,649 — Total $ 22,350,649 $ (386,419 ) $ 21,964,230 As of December 31, 2021 Indefinite life intangible - license $ 682,649 $ — $ 682,649 —

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	6 Months Ended
	Jun. 30, 2022
Payables and Accruals [Abstract]
Schedule of accrued expenses and other current liabilities	Schedule of accrued expenses and other current liabilities June 30, 2022 December 31, 2021 Accrued wages and benefits $ 5,470,145 $ 3,088,264 Current taxes payable 7,595,105 — Accrued other 4,126,010 3,776,162 Total accrued expenses and other current liabilities $ 17,191,260 $ 6,864,426

Debt (Tables)

Debt (Tables)	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Schedule of debt	Schedule of debt Maturity dates Interest rates June 30, 2022 December 31, 2021 Term loans secured by all assets 04/2023 - 11/2030 3.25 6.00 $ 10,728,901 $ 15,613,564 Term loans secured by property and equipment 01/2024 - 10/2029 4.19 6.90 7,049,839 11,190,093 Line of credit secured by all assets 07/2022 - 01/2023 4.50 6.50 2,592,714 72,055 Notes payable convertible into Nutex common shares at $1.55 per share 07/2022 10.00 % 342,963 — Term loans of consolidated Real Estate Entities 08/2022 - 12/2040 2.84 5.75 6,020,949 62,478,951 Total 26,735,366 89,354,663 Less: unamortized debt issuance costs 101,634 301,691 Less: short-term lines of credit 2,592,714 72,055 Less: current portion of long-term debt 7,735,760 10,158,932 Total debt reflected as long-term $ 16,305,258 $ 78,821,985

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2022
Leases [Abstract]
Schedule of lease of property and equipment	Schedule of lease of property and equipment Three months ended June 30 Six months ended June 30 2022 2021 2022 2021 Operating lease cost $ 862,642 $ 662,104 $ 1,555,311 $ 1,013,461 Finance lease cost: Amortization of right-of-use assets 3,539,969 572,052 4,467,633 1,129,023 Interest on lease liabilities 3,770,058 503,968 4,750,677 1,002,396 Total finance lease cost $ 7,310,027 $ 1,076,020 $ 9,218,310 $ 2,131,419
Schedule of minimum lease payments	Schedule of minimum lease payments Operating Leases Finance Leases Minimum lease payments for the next five years: Third-parties Related parties Third-parties Related parties 2022 $ 1,020,472 $ 298,260 $ 1,193,459 $ 5,666,492 2023 2,065,162 604,631 2,450,062 11,450,611 2024 2,086,611 627,080 2,129,408 11,703,516 2025 2,136,809 638,490 1,905,419 11,873,566 2026 2,035,479 662,159 1,949,506 12,049,752 2027 2,026,407 674,251 1,994,625 12,227,137 Thereafter 8,350,671 5,171,218 33,997,249 221,826,195 Total minimum lease payments 19,721,611 8,676,089 45,619,728 286,797,269 Less interest (1,722,511 ) (2,348,744 ) (17,644,332 ) (118,583,875 ) Total lease liabilities $ 17,999,100 $ 6,327,345 $ 27,975,396 $ 168,213,394

Stock-based Compensation (Table

Stock-based Compensation (Tables)	6 Months Ended
	Jun. 30, 2022
Equity [Abstract]
Schedule of stock option activities	Schedule of stock option activities Weighted Average Options Weighted Remaining Contractual Outstanding Average Life (Years) Options outstanding at April 1, 2022 merger date 6,500,010 $ 2.30 6.62 Options exercised (312,019 ) 2.08 Options outstanding at June 30, 2022 6,187,991 $ 2.30 6.17
Schedule of stock options outstanding	Schedule of stock options outstanding Expiration Number Number Exercise Date Outstanding Exercisable Price March 15, 2025 157,196 157,196 $ 2.00 January 27, 2027 180,000 180,000 1.50 May 11, 2027 350,000 350,000 1.50 June 6, 2027 3,600 3,600 0.07 August 16, 2027 25,000 25,000 2.51 September 7, 2027 2,975,000 2,975,000 2.75 September 27, 2027 410,000 410,000 2.75 December 17, 2027 157,000 157,000 3.50 January 28, 2028 180,000 180,000 1.61 January 27, 2030 296,865 296,865 1.50 February 28, 2030 95,794 95,794 1.25 June 30, 2030 117,056 117,056 1.45 August 5, 2029 40,480 40,480 5.56 January 28, 2031 1,000,000 1,000,000 1.61 February 25, 2031 200,000 200,000 2.00 Total 6,187,991 6,187,991
Schedule of Warrants, Activity	Schedule of Warrants, Activity Warrants Weighted Average Average Remaining Contractual Life Outstanding Exercise Price (Years) Warrants outstanding at April 1, 2022 merger date 12,401,240 $ 2.04 4.65 Warrants exercised (2,187,225 ) 2.27 Warrants outstanding at June 30, 2022 10,214,015 $ 2.04 4.60
Schedule of outstanding warrants	Schedule of outstanding warrants Expiration Number Number Exercise Date Outstanding Exercisable Price February 5, 2023 1,500 1,500 $ 25.00 April 27, 2023 1,500 1,500 25.00 December 31, 2024 554,873 554,873 6.67 October 31, 2025 763,701 763,701 1.25 February 26, 2026 288,236 288,236 4.00 July 31, 2026 2,532,900 2,532,900 1.55 February 1, 2027 1,456,452 1,456,452 1.55 May 30, 2027 4,614,853 4,614,853 1.75 Total 10,214,015 10,214,015

Income Taxes (Tables)

Income Taxes (Tables)	6 Months Ended
	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Schedule of income tax expense	Schedule of income tax expense Three months ended June 30 Six months ended June 30 2022 2021 2022 2021 Income taxes computed at the federal statutory rate $ (803,226 ) $ 6,333,505 $ 4,447,290 $ 17,051,034 Effect of: State taxes, net of federal benefits 675,275 481,501 675,275 638,354 Income of flow-through entities 238,172 (6,333,505 ) (4,836,021 ) (17,051,034 ) Change in tax status of Nutex Health Holdco LLC 20,775,898 — 20,775,898 — Reversal of acquired Clinigence valuation allowance (2,393,178 ) — (2,393,178 ) — Other permanent items, net 1,160,345 — 1,160,345 — Total income tax expense $ 19,653,286 $ 481,501 $ 19,829,609 $ 638,354

Earnings per Share (Tables)

Earnings per Share (Tables)	6 Months Ended
	Jun. 30, 2022
Earnings (loss) per common share
Schedule of earnings per share	Schedule of earnings per share Three months ended June 30 Six months ended June 30 2022 2021 2022 2021 Amounts attributable to Nutex Health Inc.: Numerator- Net income (loss) attributable to common stockholders $ (19,395,752 ) $ 27,059,401 $ 2,134,550 $ 64,821,537 Denominator: Weighted average shares used to compute basic EPS 646,370,173 592,791,712 619,728,949 592,791,712 Dilutive effect of convertible note 851,611 — 851,611 — Dilutive effect of common stock options 4,296,239 — 2,285,171 — Dilutive effect of common stock warrants 7,473,169 — 4,127,086 — Weighted average shares used to compute diluted EPS 658,991,192 592,791,712 626,992,817 592,791,712 Earnings (loss) per share: Basic $ (0.03 ) $ 0.05 $ 0.00 $ 0.11 Diluted $ (0.03 ) $ 0.05 $ 0.00 $ 0.11

Segment Information (Tables)

Segment Information (Tables)	6 Months Ended
	Jun. 30, 2022
Segment Reporting [Abstract]
Schedule of segment information	Schedule of segment information Three months ended June 30 Six months ended June 30 2022 2021 2022 2021 Revenues from external customers Hospital division $ 51,604,679 $ 62,814,672 $ 130,731,921 $ 150,157,914 Population health management division 6,443,254 — 6,443,254 — Total revenue 58,047,933 62,814,672 137,175,175 150,157,914 Segment operating income: Hospital division 5,249,528 29,137,332 39,647,506 83,787,175 Population health management division (257,002 ) — (257,002 ) — Total segment operating income $ 4,992,526 $ 29,137,332 $ 39,390,504 $ 83,787,175 Capital expenditures: Hospital division $ 1,364,694 $ 5,751,861 $ 3,730,053 $ 6,233,817 Real estate division 6,665,209 4,798,142 12,891,673 15,480,938 Total capital expenditures $ 8,029,903 $ 10,550,003 $ 16,621,726 $ 21,714,755 Revenue from inter-segment activities: Real estate division $ 7,943,243 $ — $ 11,989,212 $ 11,054,153 Depreciation and amortization: Hospital division $ 2,703,655 $ 1,381,394 $ 5,096,326 $ 3,155,383 Population health management division 387,984 — 387,984 — Real estate division 40,846 842,067 45,036 846,257 Total depreciation and amortization $ 3,132,485 $ 2,223,461 $ 5,529,346 $ 4,001,640
Schedule of assets	Schedule of assets As of June 30, 2022 December 31, 2021 Assets: Hospital division $ 384,426,690 $ 287,316,356 Population health management division 462,484,616 — Real estate division 24,881,954 107,333,687 Total Assets $ 871,793,260 $ 394,650,043

Variable Interest Entities (Tab

Variable Interest Entities (Tables)	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of consolidated balance sheets	Schedule of consolidated balance sheets June 30, 2022 Real Estate Physician AHP Entities LLCs IPA Current assets $ 15,991,847 $ 14,599,965 $ 25,116,483 Property and equipment, net 8,865,609 3,668 — Other long-term assets 24,500 — 17,150,197 Total assets $ 24,881,956 $ 14,603,633 $ 42,266,680 Current liabilities 2,226,930 8,584,407 2,738,537 Long-term liabilities 6,020,950 — — Total liabilities 8,247,880 8,584,407 2,738,537 Equity 16,634,076 6,019,226 39,528,143 Total liabilities and equity $ 24,881,956 $ 14,603,633 $ 42,266,680 December 31, 2021 Real Estate Physician Entities LLCs Current assets $ 10,959,090 $ 22,035,457 Property and equipment, net 32,182,902 — Long-term assets 128,870,699 4,279 Total assets $ 172,012,691 $ 22,039,736 Current liabilities 6,666,690 5,070,706 Long-term liabilities 68,850,689 930,000 Total liabilities 75,517,379 6,000,706 Equity 96,495,312 16,039,030 Total liabilities and equity $ 172,012,691 $ 22,039,736

Organization and Operations (De

Organization and Operations (Details Narrative)	6 Months Ended
	Jun. 30, 2022 shares
Ownership interests	100%
Contribution agreements, description	Such additional shares will be issued at the greater of (a) the price of the Company’s common stock at the time of determination or (b) $2.80. In addition, on the 24-month anniversary of the respective opening dates, contributing owners of under construction hospitals will be eligible to receive such owner’s pro rata share of a number of shares of Company common stock equal to (a)(i) the trailing twelve months earnings before interest, taxes, depreciation and amortization as determined on the 24th anniversary of their respective opening times (ii) ten minus (iii) the aggregate amount of such owner’s capital contribution minus (iv) such owner’s pro rata share of the aggregate debt of the applicable under construction hospital outstanding as of the Closing of the Merger divided by (b) the greater of (i) the price of the Company common stock at the time of determination or (ii) $2.80.
Common Stock [Member] | Merger Agreement [Member]
Aggregate of shares	592,791,712
Nutex Health Inc [Member]
Ownership interests	84%

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details Narrative)	Jun. 30, 2022 USD ($)
Accounting Policies [Abstract]
Ownership interests	100%
Federal Deposit Insurance Corporation	$ 250,000

Merger of Nutex Health Holdco_3

Merger of Nutex Health Holdco LLC and Clinigence Holdings, Inc. (Details)	6 Months Ended
	Jun. 30, 2022 USD ($)
Business Combination and Asset Acquisition [Abstract]
Fair value of Clinigence common shares at $6.40 per share	$ 326,151,098
Fair value of Clinigence outstanding common stock options and warrants	120,875,452
Total consideration	$ 447,026,550

Merger of Nutex Health Holdco_4

Merger of Nutex Health Holdco LLC and Clinigence Holdings, Inc. (Details 1	Jun. 30, 2022 USD ($)
Business Combination and Asset Acquisition [Abstract]
Cash and cash equivalents	$ 12,716,228
Accounts receivable, net	2,127,076
Prepaid expenses and other current assets	127,384
Property and equipment, net	14,793
Right of use asset, net	86,989
Intangible assets, net	21,668,000
Goodwill	424,216,539
Accounts payable and accrued expenses	(3,966,100)
Deferred revenue	(92,111)
Convertible notes payable, net	(3,771,858)
Term note payable	(553,150)
Lease liability	(91,238)
Deferred tax liability	(5,456,002)
Assets acquired	$ 447,026,550

Merger of Nutex Health Holdco_5

Merger of Nutex Health Holdco LLC and Clinigence Holdings, Inc. (Details 2) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Business Combination and Asset Acquisition [Abstract]
Revenue	$ 58,047,933	$ 68,105,177	$ 143,384,350	$ 157,462,764
Net income (loss) attributable to Nutex Health Inc.	$ (19,395,754)	$ 23,711,523	$ (12,215,600)	$ 56,629,242

Merger of Nutex Health Holdco_6

Merger of Nutex Health Holdco LLC and Clinigence Holdings, Inc (Details Narrative) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2022
Acquisition-related costs	$ 3,900
Pro forma loss		$ 14,200
Minimum [Member]
Estimated useful lives		5 years
Maximum [Member]
Estimated useful lives		16 years

Revenue (Details)

Revenue (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Disaggregation of Revenue [Line Items]
Revenues	$ 58,047,933	$ 62,814,672	$ 137,175,175	$ 150,157,914
Hospital Division [Member]
Disaggregation of Revenue [Line Items]
Revenues	51,604,679	62,814,672	130,731,921	150,157,914
Hospital Division [Member] | Net Patient Service Revenue [Member]
Disaggregation of Revenue [Line Items]
Revenues	51,209,741	62,347,436	130,025,739	149,260,934
Hospital Division [Member] | Management Fees [Member]
Disaggregation of Revenue [Line Items]
Revenues	394,938	467,236	706,182	896,980
Population Health Management Division [Member]
Disaggregation of Revenue [Line Items]
Revenues	6,443,254		6,443,254
Population Health Management Division [Member] | Management Fees [Member]
Disaggregation of Revenue [Line Items]
Revenues	1,002,800		1,002,800
Population Health Management Division [Member] | Capitation Revenue Net [Member]
Disaggregation of Revenue [Line Items]
Revenues	5,150,342		5,150,342
Population Health Management Division [Member] | Saas Revenue [Member]
Disaggregation of Revenue [Line Items]
Revenues	$ 290,112		$ 290,112

Revenue (Details 1)

Revenue (Details 1)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Disaggregation of Revenue [Line Items]
Insurance coverage, percentage	100%	100%	100%	100%
Insurance [Member]
Disaggregation of Revenue [Line Items]
Insurance coverage, percentage	92%	97%	92%	96%
Self Pay [Member]
Disaggregation of Revenue [Line Items]
Insurance coverage, percentage	8%	2%	8%	3%
Workers' Compensation Insurance [Member]
Disaggregation of Revenue [Line Items]
Insurance coverage, percentage	0%	1%	0%	1%
Medicare [Member]
Disaggregation of Revenue [Line Items]
Insurance coverage, percentage	0%	0%	0%	0%

Revenue (Details Narrative)

Revenue (Details Narrative) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Deferred revenue	$ 55,355	$ 0

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	6 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 78,988,286	$ 163,501,091
Less: accumulated depreciation	11,165,604	11,588,591
Total property and equipment, net	$ 67,822,682	151,912,500
Building and Building Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment useful lives	39 years
Property and equipment, gross	$ 8,572,428	82,794,329
Land [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	1,972,509	18,201,804
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 28,776,436	27,038,503
Leasehold Improvements [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment useful lives	10 years
Leasehold Improvements [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment useful lives	39 years
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 7,606,103	4,299,614
Medical Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment useful lives	10 years
Property and equipment, gross	$ 26,284,999	25,686,562
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment useful lives	7 years
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 2,864,410	2,870,270
Computer Hardware And Software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment useful lives	5 years
Property and equipment, gross	$ 1,611,434	1,288,224
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Property and equipment useful lives	5 years
Property and equipment, gross	$ 135,590	161,590
Signage [Member]
Property, Plant and Equipment [Line Items]
Property and equipment useful lives	10 years
Property and equipment, gross	$ 1,164,377	$ 1,160,195

Intangible Assets (Details)

Intangible Assets (Details) - USD ($)	6 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross	$ 22,350,649
Less: Accumulated amortization	(386,419)
Intangible Assets, Net	$ 21,964,230
Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets useful life	5 years
Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets useful life	16 years
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross	$ 16,899,000
Less: Accumulated amortization	(281,649)
Intangible Assets, Net	$ 16,617,351
Intangible assets useful life	15 years
Management Contracts [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross	$ 2,021,000
Less: Accumulated amortization	(31,578)
Intangible Assets, Net	$ 1,989,422
Intangible assets useful life	16 years
Customer Contracts [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross	$ 914,000
Less: Accumulated amortization	(15,234)
Intangible Assets, Net	$ 898,766
Intangible assets useful life	15 years
Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross	$ 1,425,000
Less: Accumulated amortization	(37,508)
Intangible Assets, Net	$ 1,387,492
Trademarks [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets useful life	7 years
Trademarks [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets useful life	12 years
P H P Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross	$ 409,000
Less: Accumulated amortization	(20,450)
Intangible Assets, Net	$ 388,550
Intangible assets useful life	5 years
Indefinite Life Intangible License [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross	$ 682,649	$ 682,649
Less: Accumulated amortization	0	0
Intangible Assets, Net	$ 682,649	$ 682,649

Intangible Assets (Details Narr

Intangible Assets (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization Expense	$ 386,419	$ 0	$ 386,419	$ 0

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities (Details) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Accrued wages and benefits	$ 5,470,145	$ 3,088,264
Current taxes payable	7,595,105
Accrued other	4,126,010	3,776,162
Total accrued expenses and other current liabilities	$ 17,191,260	$ 6,864,426

Debt (Details)

Debt (Details) - USD ($)	6 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Short-Term Debt [Line Items]
Total	$ 26,735,366	$ 89,354,663
Less: unamortized debt issuance costs	101,634	301,691
Less: short-term lines of credit	2,592,714	72,055
Less: current portion of long-term debt	7,735,760	10,158,932
Total debt reflected as long-term	$ 16,305,258	78,821,985
Term Loan [Member]
Short-Term Debt [Line Items]
Maturity date	04/2023 - 11/2030
Total	$ 10,728,901	15,613,564
Term Loan [Member] | Minimum [Member]
Short-Term Debt [Line Items]
Interest rates	3.25%
Term Loan [Member] | Maximum [Member]
Short-Term Debt [Line Items]
Interest rates	6%
Term Loan 1 [Member]
Short-Term Debt [Line Items]
Maturity date	01/2024 - 10/2029
Total	$ 7,049,839	11,190,093
Term Loan 1 [Member] | Minimum [Member]
Short-Term Debt [Line Items]
Interest rates	4.19%
Term Loan 1 [Member] | Maximum [Member]
Short-Term Debt [Line Items]
Interest rates	6.90%
Line of Credit [Member]
Short-Term Debt [Line Items]
Maturity date	07/2022 - 01/2023
Total	$ 2,592,714	72,055
Line of Credit [Member] | Minimum [Member]
Short-Term Debt [Line Items]
Interest rates	4.50%
Line of Credit [Member] | Maximum [Member]
Short-Term Debt [Line Items]
Interest rates	6.50%
Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Maturity date	07/2022
Interest rates	10%
Total	$ 342,963
Term Loan 3 [Member]
Short-Term Debt [Line Items]
Maturity date	08/2022 - 12/2040
Total	$ 6,020,949	$ 62,478,951
Term Loan 3 [Member] | Minimum [Member]
Short-Term Debt [Line Items]
Interest rates	2.84%
Term Loan 3 [Member] | Maximum [Member]
Short-Term Debt [Line Items]
Interest rates	5.75%

Debt (Details Narrative)

Debt (Details Narrative)	6 Months Ended
	Jun. 30, 2022 USD ($) shares
Short-Term Debt [Line Items]
Outstanding lines of credit	$ 1,657,000
Convertible notes payable	342,963
Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Principal amount	5,415,375
Conversion of debt	$ 4,065,375
Conversion of debt, shares | shares	2,622,819
Maturity date	Jul. 31, 2022

Leases (Details)

Leases (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Leases [Abstract]
Operating lease cost	$ 862,642	$ 662,104	$ 1,555,311	$ 1,013,461
Finance lease cost:
Amortization of right-of-use assets	3,539,969	572,052	4,467,633	1,129,023
Interest on lease liabilities	3,770,058	503,968	4,750,677	1,002,396
Total finance lease cost	$ 7,310,027	$ 1,076,020	$ 9,218,310	$ 2,131,419

Leases (Details 1)

Leases (Details 1)	Jun. 30, 2022 USD ($)
Third Parties [Member]
Defined Benefit Plan Disclosure [Line Items]
2022	$ 1,020,472
2022	1,193,459
2023	2,065,162
2023	2,450,062
2024	2,086,611
2024	2,129,408
2025	2,136,809
2025	1,905,419
2026	2,035,479
2026	1,949,506
2027	2,026,407
2027	1,994,625
Thereafter	8,350,671
Thereafter	33,997,249
Total minimum lease payments	19,721,611
Total minimum lease payments	45,619,728
Less interest	(1,722,511)
Less interest	(17,644,332)
Total lease liabilities	17,999,100
Total lease liabilities	27,975,396
Related Parties [Member]
Defined Benefit Plan Disclosure [Line Items]
2022	298,260
2022	5,666,492
2023	604,631
2023	11,450,611
2024	627,080
2024	11,703,516
2025	638,490
2025	11,873,566
2026	662,159
2026	12,049,752
2027	674,251
2027	12,227,137
Thereafter	5,171,218
Thereafter	221,826,195
Total minimum lease payments	8,676,089
Total minimum lease payments	286,797,269
Less interest	(2,348,744)
Less interest	(118,583,875)
Total lease liabilities	6,327,345
Total lease liabilities	$ 168,213,394

Employee Benefit Plans (Details

Employee Benefit Plans (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Retirement Benefits [Abstract]
Contributions to employee salary percentage			5%
Contributions to employee plan value	$ 0	$ 0	$ 0	$ 0

Stock-based Compensation (Detai

Stock-based Compensation (Details) - $ / shares	3 Months Ended
	Jun. 30, 2022	Mar. 31, 2022
Equity [Abstract]
Options, Outstanding, Beginning Balance	6,500,010
Options, Outstanding, Beginning Balance, Weighted Average Exercise Price	$ 2.30
Weighted average remaining life contractual life (years)	6 years 2 months 1 day	6 years 7 months 13 days
Options, Exercised	(312,019)
Options, Exercised, Weighted Average Exercise Price	$ 2.08
Options, Outstanding, Ending Balance	6,187,991
Options, Outstanding, Ending Balance, Weighted Average Exercise Price	$ 2.30	$ 2.30

Stock-based Compensation (Det_2

Stock-based Compensation (Details 1) - $ / shares	6 Months Ended
	Jun. 30, 2022	Mar. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Outstanding	6,187,991
Number Exercisable	6,187,991
Exercise price	$ 2.30	$ 2.30
Options One
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options outstanding Expiration Date	Mar. 15, 2025
Number of Outstanding	157,196
Number Exercisable	157,196
Exercise price	$ 2
Options Two
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options outstanding Expiration Date	Jan. 27, 2027
Number of Outstanding	180,000
Number Exercisable	180,000
Exercise price	$ 1.50
Options Three
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options outstanding Expiration Date	May 11, 2027
Number of Outstanding	350,000
Number Exercisable	350,000
Exercise price	$ 1.50
Options Four
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options outstanding Expiration Date	Jun. 06, 2027
Number of Outstanding	3,600
Number Exercisable	3,600
Exercise price	$ 0.07
Options 5 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options outstanding Expiration Date	Aug. 16, 2027
Number of Outstanding	25,000
Number Exercisable	25,000
Exercise price	$ 2.51
Options 6 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options outstanding Expiration Date	Sep. 07, 2027
Number of Outstanding	2,975,000
Number Exercisable	2,975,000
Exercise price	$ 2.75
Options 7 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options outstanding Expiration Date	Sep. 27, 2027
Number of Outstanding	410,000
Number Exercisable	410,000
Exercise price	$ 2.75
Options 8 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options outstanding Expiration Date	Dec. 17, 2027
Number of Outstanding	157,000
Number Exercisable	157,000
Exercise price	$ 3.50
Options 9 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options outstanding Expiration Date	Jan. 28, 2028
Number of Outstanding	180,000
Number Exercisable	180,000
Exercise price	$ 1.61
Options 10 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options outstanding Expiration Date	Jan. 27, 2030
Number of Outstanding	296,865
Number Exercisable	296,865
Exercise price	$ 1.50
Options 11 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options outstanding Expiration Date	Feb. 28, 2030
Number of Outstanding	95,794
Number Exercisable	95,794
Exercise price	$ 1.25
Options 12 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options outstanding Expiration Date	Jun. 30, 2030
Number of Outstanding	117,056
Number Exercisable	117,056
Exercise price	$ 1.45
Options 13 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options outstanding Expiration Date	Aug. 05, 2029
Number of Outstanding	40,480
Number Exercisable	40,480
Exercise price	$ 5.56
Options 14 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options outstanding Expiration Date	Jan. 28, 2031
Number of Outstanding	1,000,000
Number Exercisable	1,000,000
Exercise price	$ 1.61
Options 15 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options outstanding Expiration Date	Feb. 25, 2031
Number of Outstanding	200,000
Number Exercisable	200,000
Exercise price	$ 2

Stock-based Compensation (Det_3

Stock-based Compensation (Details 2) - $ / shares	3 Months Ended
	Jun. 30, 2022	Mar. 31, 2022
Equity [Abstract]
Warrants, Outstanding, Beginning Balance	12,401,240
Weighted Average Exercise Price, Beginning Balance	$ 2.04
Weighted average remaining life contractual life (years)	4 years 7 months 6 days	4 years 7 months 24 days
Warrants Outstanding, Exercised	(2,187,225)
Weighted Average Exercise Price, Exercised	$ 2.27
Warrants, Outstanding, Ending Balance	10,214,015	12,401,240
Weighted Average Exercise Price, Ending Balance	$ 2.04	$ 2.04

Stock-based Compensation (Det_4

Stock-based Compensation (Details 3)	6 Months Ended
	Jun. 30, 2022 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Outstanding	10,214,015
Number Exercisable	10,214,015
Warrants One
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price	Feb. 05, 2023
Number of Outstanding	1,500
Number Exercisable	1,500
Exercise price | $ / shares	$ 25
Warrants Two
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price	Apr. 27, 2023
Number of Outstanding	1,500
Number Exercisable	1,500
Exercise price | $ / shares	$ 25
Warrants Three
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price	Dec. 31, 2024
Number of Outstanding	554,873
Number Exercisable	554,873
Exercise price | $ / shares	$ 6.67
Warrants 4 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price	Oct. 31, 2025
Number of Outstanding	763,701
Number Exercisable	763,701
Exercise price | $ / shares	$ 1.25
Warrants 5 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price	Feb. 26, 2026
Number of Outstanding	288,236
Number Exercisable	288,236
Exercise price | $ / shares	$ 4
Warrants Six
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price	Jul. 31, 2026
Number of Outstanding	2,532,900
Number Exercisable	2,532,900
Exercise price | $ / shares	$ 1.55
Warrants Seven
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price	Feb. 01, 2027
Number of Outstanding	1,456,452
Number Exercisable	1,456,452
Exercise price | $ / shares	$ 1.55
Warrants Eight
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price	May 30, 2027
Number of Outstanding	4,614,853
Number Exercisable	4,614,853
Exercise price | $ / shares	$ 1.75

Equity (Details Narrative)

Equity (Details Narrative)	6 Months Ended
	Jun. 30, 2022 USD ($) shares
Options Held [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued | shares	312,019
Total proceeds | $	$ 644,974
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Converted principal amount | $	$ 4,065,375
Conversion of shares | shares	2,622,819
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued | shares	2,147,252
Total proceeds | $	$ 4,119,141

Income Taxes (Details)

Income Taxes (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Tax Disclosure [Abstract]
Income taxes computed at the federal statutory rate	$ (803,226)	$ 6,333,505	$ 4,447,290	$ 17,051,034
State taxes, net of federal benefits	675,275	481,501	675,275	638,354
Income of flow-through entities	238,172	(6,333,505)	(4,836,021)	(17,051,034)
Change in tax status of Nutex Health Holdco LLC	20,775,898	0	20,775,898	0
Reversal of acquired Clinigence valuation allowance	(2,393,178)	0	(2,393,178)	0
Other permanent items, net	1,160,345	0	1,160,345	0
Total income tax expense	$ 19,653,286	$ 481,501	$ 19,829,609	$ 638,354

Income Taxes (Details Narrative

Income Taxes (Details Narrative)	3 Months Ended
	Jun. 30, 2022 USD ($)
Operating Loss Carryforwards [Line Items]
Deferred tax assets	$ 2,393,178
Effective tax rate	25.20%
Nutex Health Holdco L L C [Member]
Operating Loss Carryforwards [Line Items]
Income tax expense	$ 20,775,898

Earnings per Share (Details)

Earnings per Share (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Numerator-
Net income (loss) attributable to common stockholders	$ (19,395,752)	$ 27,059,401	$ 2,134,550	$ 64,821,537
Denominator:
Weighted average shares used to compute basic EPS	646,370,173	592,791,712	619,728,949	592,791,712
Dilutive effect of convertible note	851,611	0	851,611	0
Dilutive effect of common stock options	4,296,239	0	2,285,171	0
Dilutive effect of common stock warrants	7,473,169	0	4,127,086	0
Weighted average shares used to compute diluted EPS	658,991,192	592,791,712	626,992,817	592,791,712
Earnings (loss) per share:
Basic	$ (0.03)	$ 0.05	$ 0	$ 0.11
Diluted	$ (0.03)	$ 0.05	$ 0	$ 0.11

Segment Information (Details)

Segment Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Segment Reporting Information [Line Items]
Total revenue	$ 58,047,933	$ 62,814,672	$ 137,175,175	$ 150,157,914
Total segment operating income	4,992,526	29,137,332	39,390,504	83,787,175
Total capital expenditures	8,029,903	10,550,003	16,621,726	21,714,755
Real estate division	7,943,243	0	11,989,212	11,054,153
Total depreciation and amortization	3,132,485	2,223,461	5,529,346	4,001,640
Hospital Division [Member]
Segment Reporting Information [Line Items]
Total revenue	51,604,679	62,814,672	130,731,921	150,157,914
Total segment operating income	5,249,528	29,137,332	39,647,506	83,787,175
Total capital expenditures	1,364,694	5,751,861	3,730,053	6,233,817
Total depreciation and amortization	2,703,655	1,381,394	5,096,326	3,155,383
Population Health Management Division [Member]
Segment Reporting Information [Line Items]
Total revenue	6,443,254	0	6,443,254	0
Total segment operating income	(257,002)	0	(257,002)	0
Total depreciation and amortization	387,984	0	387,984	0
Real Estate Division [Member]
Segment Reporting Information [Line Items]
Total capital expenditures	6,665,209	4,798,142	12,891,673	15,480,938
Total depreciation and amortization	$ 40,846	$ 842,067	$ 45,036	$ 846,257

Segment Information (Details 1)

Segment Information (Details 1) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Segment Reporting Information [Line Items]
Total Assets	$ 871,793,260	$ 394,650,043
Hospital Division [Member]
Segment Reporting Information [Line Items]
Total Assets	384,426,690	287,316,356
Population Health Management Division [Member]
Segment Reporting Information [Line Items]
Total Assets	462,484,616	0
Real Estate Division [Member]
Segment Reporting Information [Line Items]
Total Assets	$ 24,881,954	$ 107,333,687

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Related Party Transaction [Line Items]
Net expense recognized	$ 0		$ 1,506,650
Accounts payable	130,676		130,676		$ 0
Payments for lease obligations	3,305,798	$ 2,707,276	6,189,479	$ 5,373,106
Cash received	1,245,000
Accounts receivable - related party	1,228,442		1,228,442		1,288,354
Managerial fees with hospital division	188,417		600,971
Revenue recognized	58,047,933	$ 62,814,672	137,175,175	$ 150,157,914
Managerial Services Agreements [Member]
Related Party Transaction [Line Items]
Proceeds from related parties	1,235,486		1,558,680
Service [Member]
Related Party Transaction [Line Items]
Revenue recognized	226,532		874,440
Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Accounts payable	1,424,948		1,424,948		1,424,948
Physician LLCs [Member]
Related Party Transaction [Line Items]
Due from related parties	2,783,241		2,783,241		1,891,147
Accounts payable	2,058,701		2,058,701		2,675,195
Real Estate [Member]
Related Party Transaction [Line Items]
Net expense recognized	0		553,259
E R Entities [Member]
Related Party Transaction [Line Items]
Accounts receivable - related party	$ 162,607		$ 162,607		$ 600,044

Variable Interest Entities (VIE

Variable Interest Entities (VIEs) (Details) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Current assets	$ 148,980,554	$ 154,015,179
Property and equipment, net	67,822,682	151,912,500
Total assets	871,793,260	394,650,043
Current liabilities	56,471,027	37,690,959
Long-term liabilities	16,305,258	78,821,985
Total liabilities	305,379,017	203,069,033
Equity	525,689,827	114,651,306
Total liabilities and equity	871,793,260	394,650,043
Real Estate Entities [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Property and equipment, net	98,086,690
Total liabilities	69,638,778
Variable Interest Entity, Primary Beneficiary [Member] | Real Estate Entities [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Current assets	15,991,847	10,959,090
Property and equipment, net	8,865,609	32,182,902
Long-term assets		128,870,699
Other long-term assets	24,500
Total assets	24,881,956	172,012,691
Current liabilities	2,226,930	6,666,690
Long-term liabilities	6,020,950	68,850,689
Total liabilities	8,247,880	75,517,379
Equity	16,634,076	96,495,312
Total liabilities and equity	24,881,956	172,012,691
Variable Interest Entity, Primary Beneficiary [Member] | Physician LLCs [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Current assets	14,599,965	22,035,457
Property and equipment, net	3,668
Long-term assets		4,279
Other long-term assets
Total assets	14,603,633	22,039,736
Current liabilities	8,584,407	5,070,706
Long-term liabilities		930,000
Total liabilities	8,584,407	6,000,706
Equity	6,019,226	16,039,030
Total liabilities and equity	14,603,633	$ 22,039,736
Variable Interest Entity, Primary Beneficiary [Member] | AHP IPA [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Current assets	25,116,483
Property and equipment, net
Other long-term assets	17,150,197
Total assets	42,266,680
Current liabilities	2,738,537
Long-term liabilities
Total liabilities	2,738,537
Equity	39,528,143
Total liabilities and equity	$ 42,266,680

Variable Interest Entities (Det

Variable Interest Entities (Details Narrative) - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2022	Dec. 31, 2021
Fixed assets	$ 67,822,682	$ 67,822,682	$ 151,912,500
Other assets	441,304	441,304	456,085
Liabilities	305,379,017	305,379,017	203,069,033
Noncontrolling interests	40,724,416	40,724,416	$ 76,929,704
[custom:DeconsolidationOfRealEstateEntities]	(39,323,872)	39,323,872
Real Estate Entities [Member]
Cash	2,421,212	2,421,212
Fixed assets	98,086,690	98,086,690
Other assets	533,874	533,874
Liabilities	69,638,778	69,638,778
Noncontrolling interests	$ 1,402,998	$ 1,402,998

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - Convertible Notes Payable [Member]	6 Months Ended
	Jun. 30, 2022 $ / shares shares
Short-Term Debt [Line Items]
Number of shares converted	2,622,819
Price per share | $ / shares	$ 1.55
Common Stock [Member]
Short-Term Debt [Line Items]
Number of shares converted	851,611